挺进美女教师的蜜桃肥臀视频-同性恋一级片-同性情a三级a三级a三级-同性做爰猛烈全过程-91丨porny丨国产麻豆-91丨porny丨国产入口

 Biocept Laboratories,  
成立于1997年,循環腫瘤細胞（circulating tumor cells,CTCs）檢測診斷公司.


Biocept Laboratories is molecular oncology laboratory services company specializing in Circulating Tumor Cells (CTCs) and biomarker analysis, headquartered in San Diego, California. Our mission is to impact the lives of cancer patients through innovative diagnostic products and services.

We utilize patented and innovative technologies to deliver clinically relevant oncology laboratory tests to physicians that provide advanced prognostic and predictive assessments for guiding the course of treating patients. Additionally, we offer services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. The products we provide include a detailed report with the results and interpretations of the requested tests.

Strategic Focus

Our strategic focus is to promote our unique technology (CEE?- cell enrichment and extraction) and family of laboratory tests (OncoCEE?) to high-value oncology prospects. The CEE?system has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. Examples of these rare cells are circulating tumor cells (CTCs) in patients with early-stage, metastatic or recurrent cancers. We will distinguish our rare cell analysis from competitive methods, specifically in cancer diagnostic tests and services, with non-invasive prognostic and predictive information not currently offered by commercial laboratories.

We employ our unique laboratory tests through an offering of services to medical/surgical oncologists, pathologists, hospitals, cancer centers, universities, and pharmaceutical/clinical researchers. We are able to differentiate ourselves from competitive technologies and expand our menu of laboratory tests based upon our intellectual properties, various non-invasive sample types, our expansion into additional solid tumor types, and the support of major cancer centers.